National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.


Rapid Review

Commenced Completed Outcome
08/12/2014 30/12/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
04/06/2015 16/02/2016 Reimbursement Not Recommended


The HSE has approved reimbursement following confidential price negotiations December 2016.